GlassScriptPhysician profile
David Schwindt
NPI 1366489536
$4,756.21
in general payments reported to CMS, 2019-2025
26 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $340 · 2021: $618 · 2022: $623 · 2023: $840 · 2024: $484 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,093.23 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $548.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $546.40 | 2020-2025 | Airsupra |
| Allergan, INC. | $361.28 | 2019-2020 | |
| Saluda Medical Americas, INC. | $277.22 | 2023-2025 | Evoke, Evoke Scs |
| Amarin Pharma, INC. | $230.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $201.18 | 2019-2023 | Spravato |
| Novo Nordisk INC | $188.50 | 2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.26 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $157.43 | 2022-2024 | Rexulti |
| Madrigal Pharmaceuticals | $128.24 | 2025 | Rezdiffra |
| Nevro Corp. | $121.55 | 2022 | |
| Boston Scientific Corporation | $118.59 | 2021 | |
| Vertos Medical, INC. | $88.89 | 2023 | Mild Device Kit |
| Abbott Laboratories | $85.06 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $78.13 | 2025 | Mild Device Kit |
| Axsome Therapeutics, INC. | $73.86 | 2023 | Auvelity |
| Lilly USA, LLC | $65.62 | 2022-2025 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $56.32 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $52.63 | 2022-2023 | Belsomra, Steglatro, Steglujan |
| Coloplast Corp | $31.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.30 | 2025 | Xifaxan |
| Ibsa Pharma INC. | $19.43 | 2023 | Tirosint, Licart |
| Exact Sciences Corporation | $17.24 | 2024 | Cologuard Collection Kit |
| Verona Pharma, INC. | $15.64 | 2025 | Ohtuvayre |
| Pfizer INC. | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwindt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.